Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $20.3252W HIGH $40.22
Volume
395.26 K
Value Traded
13.70 M
Short % Float
19.18%
Days to Cover
12.3
-2.74%Week
+1.49%1 Month
-11.94%3 Month
-22.35%6 Month
-21.3%5 Year
+7.83%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.69 B
EPS (TTM)
-2.35
P/E Ratio
-
Ent. Value
1.34 B
Total Shares
64.53 M
Float Shares
53.49 M
Insiders
17.10%
Institutions
113.38%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
STOK Catalyst Timeline
Dated clinical, regulatory and corporate events for Stoke Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Stoke Therapeutics, Inc.
286Total events
17Upcoming
46Tier-1 (high impact)
2019 to 2028Coverage
Upcoming catalysts 2
Event history 50
●Oral PresentationSTK-002Presentation
Stoke presents STK-002 preclinical and natural history data at AAO 2026
Autosomal Dominant Optic Atrophy (ADOA)source ↗
▲End Of Phase 2 MeetingzorevunersenFDA Meeting
Completion of successful FDA meeting to align on planned U.S. NDA for zorevunersen
Dravet syndromesource ↗
▲Pre NDA MeetingzorevunersenFDA Meeting
Completion of successful FDA meeting to align on planned U.S. NDA for zorevunersen
Dravet syndromesource ↗
▲Preclinical PoCSTK-002Preclinical
Preclinical proof-of-concept data for STK-002 in ADOA presented at AAO 2026
Autosomal Dominant Optic Atrophy (ADOA)source ↗
●Management ChangeCorporate
Edward Kaye, M.D. retires from Stoke Therapeutics Board of Directors
●Oral PresentationzorevunersenPresentation
Presentations of long-term clinical data at the 16th European Epilepsy Congress (EEC)
Dravet syndromesource ↗
●R&D DayPresentation
Stoke Therapeutics to present at Canaccord Genuity 46th Annual Growth Conference
▲Long Term DatazorevunersenClinical Data
New 4-year longitudinal data from OLE studies announced
Dravet syndromesource ↗
●Quarterly UpdateCorporate
Stoke Therapeutics to host Q2 2026 business and financial update webcast and conference call
▲Enrollment CompletezorevunersenTrial
Completion of enrollment of additional cohort of 34 patients in Europe
Dravet syndromesource ↗
◆Dose Finding UpdateSTK-002Trial
Dosing of second cohort expected to begin
Autosomal Dominant Optic Atrophy (ADOA)source ↗
◆Timing GuidancezorevunersenPresentation
First patients expected to reach Week 52
Dravet syndromesource ↗
▲Enrollment CompletezorevunersenTrial
Completion of enrollment of 162 patients into Phase 3 EMPEROR study
Dravet Syndromesource ↗
◆Oral PresentationPresentation
Stoke Therapeutics to present at Goldman Sachs Global Healthcare Conference
◆Oral PresentationPresentation
Stoke Therapeutics to present at Jefferies Global Healthcare Conference
◆Oral PresentationPresentation
Stoke Therapeutics to present at Goldman Sachs 47th Annual Global Healthcare Conference 2026
◆Oral PresentationPresentation
Stoke Therapeutics to present at 2026 Jefferies Global Healthcare Conference
▲Enrollment CompletezorevunersenTrial
Completion of enrollment in the United States, United Kingdom and Japan
Dravet syndromesource ↗
▼Equity OfferingCorporate
ATM sale to a single investor generated $65.7 million in net proceeds
●Quarterly UpdateCorporate
Webcast and conference call to discuss first quarter 2026 business and financial updates
▲Full ResultszorevunersenClinical Data
New 4-year longitudinal data from Phase 1/2a OLE studies announced
Dravet syndromesource ↗
▲Trial InitiationSTK-002Trial
Phase 1 OSPREY study underway
Autosomal Dominant Optic Atrophy (ADOA)source ↗
◆Oral PresentationPresentation
Presentation at 25th Annual Needham Virtual Healthcare Conference
◆Enrollment CompletezorevunersenTrial
Enrollment completion of approximately 150 patients in EMPEROR study expected in Q2 2026
Dravet syndromesource ↗
●Oral PresentationzorevunersenPresentation
Data presented at AAN Annual Meeting in April
Dravet syndromesource ↗
▲PublicationzorevunersenPresentation
NEJM publication of Phase 1/2a and OLE data for zorevunersen in Dravet syndrome
Dravet syndromesource ↗
◆Oral PresentationPresentation
Stoke Therapeutics to present at TD Cowen 46th Annual Health Care Conference
▲PublicationzorevunersenPresentation
Results from Phase 1/2a and OLE studies published in NEJM
Dravet syndromesource ↗
▲Full ResultszorevunersenClinical Data
Results from Phase 1/2a and OLE studies published in NEJM
Dravet syndromesource ↗
◆Oral PresentationPresentation
CEO Ian F. Smith presents at Guggenheim Emerging Outlook: Biotech Summit 2026
▲First Patient DosedSTK-002Trial
First patient dosed in Phase 1 OSPREY study of STK-002
Autosomal Dominant Optic Atrophy (ADOA)source ↗
▲First Patient DosedSTK-002Trial
First patient dosed in Phase 1 OSPREY study of STK-002 in February
Autosomal Dominant Optic Atrophy (ADOA)source ↗
◆FDA Feedback ReceivedzorevunersenFDA Meeting
Multidisciplinary meeting with FDA; FDA requested additional information
Dravet syndromesource ↗
◆Trial InitiationSTK-002Trial
European sites expected to activate in early 2026
Autosomal Dominant Optic Atrophy (ADOA)source ↗
◆Oral PresentationzorevunersenPresentation
Data presentations at 2025 AES Annual Meeting
Dravet syndromesource ↗
◆Oral PresentationzorevunersenPresentation
Propensity score weighted analysis comparing zorevunersen to natural history presented at AES 2025
Dravet syndromesource ↗
◆Enrollment UpdatezorevunersenTrial
EMPEROR study currently enrolling patients in the US
Dravet syndromesource ↗
◆Poster PresentationzorevunersenPresentation
Poster presentation at AES 2025 (Poster 3.489)
Dravet syndromesource ↗
◆Poster PresentationzorevunersenPresentation
Poster presentation at AES 2025 (Poster 2.341)
Dravet syndromesource ↗
◆Poster PresentationzorevunersenPresentation
Poster presentation at AES 2025 (Poster 1.379)
Dravet syndromesource ↗
◆Oral PresentationzorevunersenPresentation
Data presentations at 2025 AES Annual Meeting
Dravet syndromesource ↗
◆Enrollment UpdatezorevunersenTrial
EMPEROR study currently enrolling patients in the US
Dravet syndromesource ↗
Past FDA Catalysts and PDUFA Decisions
How STOK actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-11 | STK-002 | Phase 1 data presentation | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
2
Drugs Scored
rNPV / MCap
Top Drug
Top 41%
Micro Cap(rank 270 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| zorevunersen RNA therapyNCT04740476 | Dravet Syndrome | Phase 3 | ACTIVE NOT_RECRUITING | 230 | Mar 31, 2029 | ||||||
| STK-001- Single Ascending Doses Small moleculeCompletedNCT04442295 | Dravet Syndrome | Phase 1 | COMPLETED | 62 | Nov 14, 2023 |
Clinical Trial Results
Readouts, endpoints and source filings for every STOK program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| zorevunersen BreakthroughOrphanRare Pediatric | Dravet syndrome | Phase 1/2a | 2026-09-03 | substantial and durable reductions in seizures; continuing improvements in cognition and behavior; substantial reductions in the most severe seizure types; substantial improvements in quality of life through 28 months of treatmentRead More | Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Allan JonathanOfficer (GENERAL COUNSEL & CORP SEC) | Sell | -627 20,598 held | $26.33 | 10/02/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in STOK
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RTW INVESTMENTS, LP | 1.6 % (-11.1 %) | 184.00 M | 5.62 M |
STOK Institutional Ownership Trends
STOK Short Interest
Shares sold short, counted twice a month.
19.18%
Short % of Float
of tradable shares sold short
10.3M
Shares Sold Short
-10.9% vs prior count
12.3 Very high
Days to Cover
trading days of normal volume to buy every short share back
831.8K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How STOK ranks across every disease it competes in
Competitive Position is a premium feature
See how STOK ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSTOK News
STOKStoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2026 Business and Financial Updates
Stoke Therapeutics will host a webcast and conference call on October 29, 2026, at 4:30 p.m. to discuss third-quarter business and financial updates. The event targets analysts and investors seeking insights into the company's current performance. Stoke continues to develop zorevunersen as a potential disease-modifying treatment for Dravet syndrome. Management will address strategic progress during the scheduled session.
Read more →STOKStoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Stoke Therapeutics announced stock option grants to its new Senior VP and 17 other employees as part of their employment inducement under Nasdaq rules. The options, priced at $24.61 per share, will vest over four years. The company continues to develop zorevunersen, a potential treatment for Dravet syndrome, currently in Phase 3 trials.
Read more →STOKStoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting
Stoke Therapeutics has presented data supporting the disease-modifying potential of STK-002 for Autosomal Dominant Optic Atrophy (ADOA) at the AAO 2026 Annual Meeting. This novel treatment approach aims to address the most common inherited optic nerve disorder. The conference presentation underscores the significance of their findings.
Read more →STOKStoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting
Stoke Therapeutics has announced two presentations of its investigational medicine STK-002 at the upcoming American Academy of Ophthalmology (AAO) 2026 Annual Meeting. The event is scheduled for October 9-12 in New Orleans. STK-002 aims to address the root cause of Autosomal Dominant Optic Atrophy (ADOA) by enhancing OPA1 expression.
Read more →STOKStoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
Stoke Therapeutics has successfully completed a meeting with the FDA to discuss the planned New Drug Application (NDA) for zorevunersen, an investigational treatment for Dravet syndrome. This meeting aimed to align on critical aspects of the NDA process, marking a significant step forward for the company's lead product. Zorevunersen is positioned as a first-in-class therapy with the potential to modify the disease.
Read more →STOKStoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization
Stoke Therapeutics has appointed Bo Cumbo to its Board of Directors to strengthen its commercial strategy as it progresses zorevunersen, a potential treatment for Dravet syndrome, toward FDA approval. This move comes alongside the retirement of Edward Kaye, M.D. The company aims to leverage Cumbo's expertise to enhance its development efforts.
Read more →STOKStoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
Stoke Therapeutics and Biogen presented long-term clinical data at the 16th European Epilepsy Congress, highlighting the investigational medicine zorevunersen's potential in treating Dravet syndrome. The Phase 1/2a open-label extension studies showed significant reductions in seizures and improvements in cognition and behavior over four years. Zorevunersen was generally well tolerated, with ongoing studies expected to support a rolling NDA submission to the FDA by late 2027.
Read more →STOKStoke Therapeutics to Present at the Cantor Global Healthcare Conference
Stoke Therapeutics announced that its CEO Ian F. Smith and Chief Patient Officer Jason Hoitt will present at the Cantor Global Healthcare Conference. The company is known for its work in RNA medicine, particularly its lead investigational drug, zorevunersen, aimed at treating Dravet syndrome. This presentation highlights the company's commitment to advancing its innovative therapies.
Read more →STOKStoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
Stoke Therapeutics and Biogen presented promising data on zorevunersen at the 16th European Epilepsy Congress, highlighting its potential as a disease-modifying treatment for Dravet syndrome. Four-year results from Phase 1/2a studies showed sustained cognitive and behavioral improvements, alongside significant seizure reduction. The ongoing Phase 3 EMPEROR study aims to further evaluate zorevunersen's efficacy and safety.
Read more →STOKStoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
Stoke Therapeutics, a biotechnology company focused on RNA medicine, announced that its CEO Ian F. Smith and Chief Patient Officer Jason Hoitt will present at the Canaccord Genuity 46th Annual Growth Conference. The company is developing zorevunersen as a potential disease-modifying treatment for Dravet syndrome, showcasing its commitment to advancing therapeutic options.
Read more →STOK▲ +7.1%on this newsshared move
Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates
Stoke Therapeutics has announced its financial results for the second quarter of 2026, highlighting progress in the development of zorevunersen, a potential treatment for Dravet syndrome. The company continues to focus on leveraging RNA medicine to restore protein expression. Business updates reflect ongoing advancements in their clinical programs.
Read more →STOKStoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updates
Stoke Therapeutics, a biotechnology firm, is set to host a webcast and conference call on August 3, 2026, to provide business and financial updates. The company is advancing its investigational medicine, zorevunersen, aimed at treating Dravet syndrome. This event will facilitate communication with analysts and investors.
Read more →STOK▼ -6.1%on this news
Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer
Stoke Therapeutics has appointed Thomas McCauley, Ph.D., as its new Chief Scientific Officer. This strategic move is expected to enhance the company's research capabilities and drive innovation. McCauley's expertise may lead to advancements in Stoke's therapeutic development.
Read more →STOKStoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
Stoke Therapeutics has successfully completed the enrollment of 162 patients in the Phase 3 EMPEROR study for Zorevunersen, aimed at treating Dravet Syndrome. This milestone reflects the company's commitment to advancing research in rare diseases. The study's progress is expected to contribute valuable insights into the efficacy of the investigational medicine.
Read more →STOKStoke Therapeutics to Present at Upcoming Investor Conferences in June 2026
Stoke Therapeutics, a biotechnology firm focused on RNA medicine, announced that its CEO and Chief Patient Officer will present at two investor conferences in June 2026. The presentations will highlight the company's lead investigational medicine, zorevunersen, which is in Phase 3 development for Dravet syndrome. The events will be webcasted live and archived on the company's website.
Read more →STOKStoke Therapeutics to Present at Upcoming Investor Conferences in June
Stoke Therapeutics is scheduled to present at several investor conferences in June. The details of the presentations and the specific conferences have not been disclosed in the article. This event may provide insights into the company's future plans and developments.
Read more →About Stoke Therapeutics, Inc.
Headquarters45 WIGGINS AVENUE, BEDFORD, MA, 01730
BIOPHARMAWATCH ELITE PLUS
Trade the next STOK catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime